HealthTech startup Nul has raised $1m seed funding to develop its platform helping people to reduce their alcohol consumption.

Founded by Matus Maar, a former VC and co-founder of Talis Capital, Nul combines clinical care and prescription medication, digital treatment pathways and behavioural support.

Following the 2023 venture capital downturn, Maar found himself drinking daily – and took the opportunity to go travelling with his family and reset.
When he returned he founded Nul in London. The company’s programme is based on naltrexone, a medication used to reduce alcohol cravings by targeting reward pathways.

The round was led by dmg ventures and BYVP, with participation from angel investors.